Frontiers in Drug Safety and Regulation (Nov 2023)

Promising treatment biomarkers in asthma

  • Barbara Bonnesen,
  • Jens-Ulrik S. Jensen,
  • Jens-Ulrik S. Jensen,
  • Alexander G. Mathioudakis,
  • Alexander G. Mathioudakis,
  • Alexandru Corlateanu,
  • Pradeesh Sivapalan,
  • Pradeesh Sivapalan

DOI
https://doi.org/10.3389/fdsfr.2023.1291471
Journal volume & issue
Vol. 3

Abstract

Read online

Asthma is a highly heterogenous disease which researchers over time have attempted to classify into different phenotypes and endotypes to improve diagnosis, prognosis and treatment. Earlier classifications based on reaction to environmental allergens, age, sex and lung function have evolved, and today, the use of precision medicine guided by biomarkers offers new perspectives on asthma management. Identifying biomarkers that may reveal the underlying pathophysiology of the disease will help to select the patients who will benefit most from specific treatments. This review explores the classification of asthma phenotypes and focuses on the most recent advances in using biomarkers to guide treatment.

Keywords